Physician profile
Sarah Gray
NPI 1619416351
$6,178.18
in general payments reported to CMS, 2019-2025
39 companies · $351 in 2025
The $351 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,804 · 2022: $1,098 · 2023: $798 · 2024: $1,128 · 2025: $351.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,277.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,276.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,592.24 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Abbvie INC. | $880.90 | 2021-2025 | |
| Amgen INC. | $632.59 | 2021-2024 | Repatha, Otezla, Evenity |
| Esperion Therapeutics, INC. | $453.80 | 2021-2024 | Nexletol |
| Abbott Laboratories | $262.76 | 2021-2025 | Freestyle Libre 3, Proclaim |
| Astrazeneca Pharmaceuticals LP | $236.65 | 2021-2024 | Airsupra, Breztri, Farxiga |
| Biohaven Pharmaceuticals, INC. | $227.23 | 2021 | |
| Lilly USA, LLC | $169.62 | 2021-2024 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $155.34 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $154.33 | 2021-2023 | Jardiance |
| Idorsia Pharmaceuticals US INC | $145.36 | 2023-2024 | Quviviq |
| Janssen Pharmaceuticals, INC | $141.42 | 2021 | |
| Eisai INC. | $128.87 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $127.05 | 2025 | |
| Axsome Therapeutics, INC. | $122.23 | 2025 | Auvelity |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Gray listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.